ATOS

ATOS

USD

Atossa Therapeutics Inc. Common Stock

$0.855+0.012 (1.471%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.843

Hoch

$0.900

Tief

$0.843

Volumen

0.02M

Unternehmensfundamentaldaten

Marktkapitalisierung

110.5M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.62M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $0.55Aktuell $0.855Hoch $1.81

Ähnliche Nachrichten

GlobeNewswire

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today

Mehr anzeigen
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
GlobeNewswire

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today

Mehr anzeigen
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
GlobeNewswire

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today

Mehr anzeigen
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
Analyst Upgrades

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics with a Buy and raises the price target from $7 to $7.25.

Mehr anzeigen
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.